The use of vasopressin receptor antagonists in hyponatremia

被引:0
作者
Khanna, Apurv [1 ]
Menon, Madhav C. [1 ]
机构
[1] SUNY Upstate Med Univ, Dept Med, Syracuse, NY 13210 USA
关键词
Cirrhosis; congestive heart failure; hyponatremia; syndrome of inappropriate antidiuretic hormone secretion; vasopressin antagonist; CONGESTIVE-HEART-FAILURE; ANTIDIURETIC-HORMONE SIADH; V-2-RECEPTOR ANTAGONIST; SERUM SODIUM; HYPERVOLEMIC HYPONATREMIA; INAPPROPRIATE SECRETION; PHARMACOLOGICAL PROFILE; IMPROVES HYPONATREMIA; RANDOMIZED-TRIAL; ORAL TOLVAPTAN;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hyponatremia is the most prevalent electrolyte disorder in hospitalized patients. Vasopressin plays an important role in the pathogenesis of this disorder through its action on the vasopressin type 2 receptor (V(2)R), leading to electrolyte-free water reabsorption. Multiple vasopressin receptor antagonists have recently been developed that differ in their specificity for V(2)R and V(1)R. These agents have applications in diseases that can result in hypervolemic and euvolemic hyponatremia, such as the syndrome of inappropriate antidiuretic hormone secretion, congestive heart failure and cirrhosis. V(2)R antagonists have demonstrated promise in the short-term correction of hyponatremia, although the long-term survival benefits of these drugs are less clear. This review discusses the physiology of vasopressin in hyponatremia, the clinical implications of the disorder and examples of individual therapeutics used in treatment strategies.
引用
收藏
页码:1007 / 1014
页数:8
相关论文
共 47 条
  • [1] Aquaretic efect of Lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients
    Abraham, WT
    Shamshirsaz, AA
    McFann, K
    Oren, RM
    Schrier, RW
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (08) : 1615 - 1621
  • [2] Efficacy and safety of oral rehydration solution with reduced osmolarity in adults with cholera: a randomised double blind clinical trial
    Alam, NH
    Majumder, RN
    Fuchs, GJ
    [J]. LANCET, 1999, 354 (9175) : 296 - 299
  • [3] Efficacy and Safety of Oral Conivaptan, a Vasopressin-Receptor Antagonist, Evaluated in a Randomized, Controlled Trial in Patients With Euvolemic or Hypervolemic Hyponatremia
    Annane, Djillali
    Decaux, Guy
    Smith, Neila
    [J]. AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2009, 337 (01) : 28 - 36
  • [4] [Anonymous], 2006, NATL PBM DRUG MONOGR, P1
  • [5] ANTIDIURETIC-HORMONE AND THE PATHOGENESIS OF WATER-RETENTION IN CIRRHOSIS WITH ASCITES
    ARROYO, V
    CLARIA, J
    SALO, J
    JIMENEZ, W
    [J]. SEMINARS IN LIVER DISEASE, 1994, 14 (01) : 44 - 58
  • [6] *AST PHARM, 2007, VAPR PACK INS
  • [7] Oral Tolvaptan Is Safe and Effective in Chronic Hyponatremia
    Berl, Tomas
    Quittnat-Pelletier, Friederike
    Verbalis, Joseph G.
    Schrier, Robert W.
    Bichet, Daniel G.
    Ouyang, John
    Czerwiec, Frank S.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 21 (04): : 705 - 712
  • [8] Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects
    Burnier, M
    Fricker, AF
    Hayoz, D
    Nussberger, J
    Brunner, HR
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 55 (09) : 633 - 637
  • [9] Chan PS, 1998, ADV EXP MED BIOL, V449, P439
  • [10] Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia
    Finley, John J.
    Konstam, Marvin A.
    Udelson, James E.
    [J]. CIRCULATION, 2008, 118 (04) : 410 - 421